New centre at Bradford Hospital improves care for patients with wet Age-Related Macular Degeneration
- Bradford Teaching Hospitals NHS Foundation Trust and Bayer, open a new Macula Centre to improve services for patients with wet Age-related Macular Degeneration (wet AMD)
- New centre is set to increase the Trust’s capacity to assess and treat more patients in the region
- New scanning equipment available will improve diagnosis and monitoring of eye conditions for patients
Reading, 20 September 2017 - Working in partnership with Bayer, the Bradford Teaching Hospitals NHS Foundation Trust (BTHFT), has today opened a new centre to expand and improve access to care for people living with a condition that is one of the leading causes of vision loss in adults – age-related macular degeneration (AMD). This new service will increase the capacity of the existing unit and ease pressure on the service to deliver timely and high quality care for patients.
Vision loss caused by eye conditions, such as wet AMD, are some of the most common causes of vision loss in the western world. It can have a devastating impact on a person’s independence and quality of life if they are not treated effectively. Due to the number of patients requiring treatment for these conditions, eye services across the UK have been struggling to see and treat patients in a timely manner to prevent vision loss. Units are forced to postpone appointments, resulting in delayed assessment and treatment that can put patients’ sight at risk.
To help with this challenge Bradford Macula Centre, has increased its capacity to treat patients by opening a new centre equipped with sophisticated scanning equipment, capable of detecting and monitoring a number of eye conditions. Bayer has funded a new Optical Coherence Tomography scanner for the unit.
Commenting, on the new centre Consultant Ophthalmic Surgeon, Helen Devonport, said “The new centre has enabled us to increase the number of clinics from five per week, run over two and a half days, to 10 clinics per week over 5 days. In addition the number of patients that we can see per clinic has increased so we have more than doubled our capacity. This will result in new patients being seen and treated earlier and follow up patients being seen on time, both of which we know improve the outcomes for our patients”.
The new scanning equipment available at the Bradford Macula Centre will also enable the service to improve the experience of diagnosis and monitoring of eye conditions for patients. These sophisticated tools, allow healthcare professionals to take detailed images of the back of the eye, enabling accurate detection, monitoring and management of any changes to the retina. Patients visiting the centre will no longer have to go through invasive and sometimes unpleasant tests.
Bayer is dedicated to working in partnership with the ophthalmology community to help transform lives and a key focus is to work collaboratively to develop bespoke solutions to improve retinal services across the UK.
Commenting on Bayer’s collaboration with BTHFT, Dr Jackie Napier, Medical Director for Ophthalmology at Bayer said: “Bayer is dedicated to help the lives of those living with eye conditions. We are proud to support NHS Trusts across the UK to improve retinal services and care for people with sight-threatening eye conditions. We need to continue to work together as an ophthalmology community to overcome challenges in service delivery so we can preserve patients’ sight as much as possible.”
Tel : 01636 563251
E-Mail : firstname.lastname@example.org
Notes to Editors
About wet AMD
Wet AMD is a type of degenerative eye condition that affects the central part of the retina at the back of the eye, called the macula. It is caused by the growth of abnormal and fragile blood vessels beneath the macula that bleed and leak causing problems with central vision.3 The macula is the part of the eye responsible for sharp, central vision which allows us to see objects clearly, in detail, right in front of us.
Wet AMD distorts central vision, making it blurry with straight lines appearing crooked or wavy. Over time, it may cause a blank patch in central vision.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.co.uk
- RNIB. Key information and statistics on sight loss. Available at:https://www.rnib.org.uk/professionals/knowledge-and-research-hub/key-information-and-statistics (Last accessed: September 2017)
- Surveillance of Sight Loss due to delay in ophthalmic review in the UK: Frequency, cause and outcome, Mr Barny Foot, Professor Caroline MacEwen - www.rcophth.ac.uk/standards-publications-research/the-british-ophthalmological-surveillance-unit-bosu/abstract-surveillanceof-sight-loss-due-to-delay-in-ophthalmic-review-in-the-uk/
- RNIB. Age-related macular degeneration. Available at: www.rnib.org.uk/eyehealth/eyeconditions/conditionsac/Pages/amd.aspx. (Last accessed: September 2017)